Safety of treatment regimens in multiple drug resistant tuberculosis patients compiled as per the new WHO recommendations as of 2019

The objective : safety assessment of chemotherapy regimens compiled in accordance with the recommendations of World Health Organization (WHO), 2019, in patients with multiple drug resistant tuberculosis (MDR) in clinical practice settings. Subjects : Frequency, patterns, severity and risk factors of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Tuberkulëz i bolezni lëgkikh Ročník 98; číslo 1; s. 5 - 15
Hlavní autoři: Ivanova, D. A., Borisov, S. E., Rodina, O. V., Filippov, A. V., Ivanushkina, T. N., Litvinova, N. V.
Médium: Journal Article
Jazyk:ruština
Vydáno: New Terra Publishing House 12.02.2020
Témata:
adverse reactions
multiple drug resistance of tuberculosis mycobacteria
risk factors
tuberculosis
ISSN:2075-1230, 2542-1506
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The objective : safety assessment of chemotherapy regimens compiled in accordance with the recommendations of World Health Organization (WHO), 2019, in patients with multiple drug resistant tuberculosis (MDR) in clinical practice settings. Subjects : Frequency, patterns, severity and risk factors of adverse events (AE) of chemotherapy regimens compiled in accordance with the WHO recommendations as of 2019 were analyzed in 122 patients with MDR and XDR respiratory tuberculosis within programmatic use of new anti-tuberculosis drugs. Results . The frequency of AE made 64.8% (95% CI 55.9-72.7%), gastrointestinal, cardiovascular and allergic events prevailed, the comorbidity was the risk factor of AE development (OR 6.44; 95% CI 1.91-21.76). AEs of with severity degrees 3-4 were observed in 24.6% (95% CI 17.8-33.0%), neurotoxic, ototoxic and hepatotoxic reactions prevailed; risk factors included female sex (OR 3.15, 95% CI 1.32-7.53) and complications of chemotherapy in the past (OR 3.50%, 95% CI 1.49-8.70). At least one anti-tuberculosis drug was canceled due to AE in 26.2% (95% CI 19.2-34.7%), and any of Group A drugs was canceled during the first 6 months of chemotherapy in 13.9% (95% CI 8.8-21.3%) of patients.
ISSN:2075-1230
2542-1506
DOI:10.21292/2075-1230-2020-98-1-5-15